• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

    2/27/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025.

    "In 2024, we began rebalancing our pipeline to focus on XmAb® drug candidates that leverage our protein engineering strengths and reduce exposure to biological uncertainties—changes we believe increase our overall opportunities for clinical success. We are enthusiastic about ongoing advancement within our oncology portfolio of T-cell engager programs that are nearing important clinical inflection points. We have also introduced several candidates to be developed for patients with autoimmune disease, where there is a great need for new therapeutic agents beyond standard of care, and many of these programs will reach clinical milestones this year," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.

    "In the first half of 2025, we look forward to presenting initial first-in-human healthy volunteer data for XmAb942, our potentially best-in-class, high potency, anti-TL1A antibody with extended half-life, which we are developing for people living with inflammatory bowel disease. In the second half of the year, we plan to present data from our Phase 1 dose-escalation study of XmAb819, our bispecific T-cell engager targeting ENPP3 in ccRCC at a major medical meeting."

    Clinical Program Updates and 2025 Priorities

    • XmAb942 (Xtend™ anti-TL1A), a potential best-in-class, high-potency, extended half-life antibody in development for patients with inflammatory bowel disease. In the fourth quarter of 2024, Xencor initiated dosing of healthy volunteers in the first-in-human study of XmAb942. In the first half of 2025, Xencor will present initial data from the single-ascending dose portion of the study. In the second half of 2025, Xencor will present data from the multiple-ascending dose portion of the study and plans to initiate a Phase 2 study in participants with ulcerative colitis.



    • XmAb819 (ENPP3 x CD3), a first-in-class, tumor-targeted, T-cell engaging 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC). XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3. Xencor is conducting a Phase 1 study to evaluate XmAb819 in patients with advanced ccRCC and plans to present initial data at a medical conference during the second half of 2025.



    • XmAb541 (CLDN6 x CD3), a first-in-class, tumor-targeted, T-cell engaging 2+1 bispecific antibody in development for patients with advanced solid tumors expressing CLDN6. Like XmAb819, XmAb541 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing CLDN6. The 2+1 multivalent format enables greater selectivity for targeting the tumor-associated antigen CLDN6 over similar Claudin family members, and new preclinical data demonstrating this selectivity were presented in January 2025. A Phase 1 dose-escalation study to evaluate XmAb541 in patients with ovarian cancer and other CLDN6-expressing tumor types is ongoing, with characterization of target dose levels anticipated to begin during 2025.



    • XmAb808 (B7-H3 x CD28), a bispecific antibody to provide conditional co-stimulation of T cells when also bound to tumor cells. Dose escalation in an ongoing Phase 1 study combining XmAb808 with pembrolizumab resumed late in the fourth quarter of 2024, and enrollment in the final dose-escalation cohort is complete. To date a maximum tolerated dose has not been reached, and data from the study are expected to inform future development decisions for the program. Xencor does not plan to initiate expansion cohorts in combination with pembrolizumab. Potential combination with CD3 T-cell engaging bispecific antibodies is being evaluated.



    • Vudalimab (PD-1 x CTLA-4), a bispecific antibody that targets two immune checkpoint receptors for selective activation of T cells. In the fourth quarter of 2024, we completed enrollment in two studies of vudalimab in patients with metastatic castration-resistant prostate cancer (mCRPC) and in Part 1 of a study in patients with locally advanced or metastatic non-small cell lung cancer. Xencor has paused further development of vudalimab and has prioritized resources to advance other pipeline programs. Safety data from the three studies of vudalimab remain consistent with prior data disclosures.

    Upcoming Clinical Study Initiation Plans

    • Plamotamab (CD20 x CD3), a clinical stage, B-cell depleting bispecific T-cell engager for development in rheumatoid arthritis (RA). Data demonstrating deep peripheral B-cell depletion observed in patients with lymphoma were presented at a medical meeting in December 2024. Xencor plans to evaluate plamotamab in RA, in which patients have progressed through prior standard-of-care treatment and initiate a Phase 1b/2a proof-of-concept study in the first half of 2025. The Phase 1b portion of the study will select a priming and step-up dose regimen based on the regimen established in oncology and will assess the initial safety, efficacy, and biomarkers of plamotamab in patients with RA. The selected dose regimen will then be evaluated in the randomized Phase 2a portion, with efficacy determined at week 12.



    • XmAb657 (CD19 x CD3), a potent, extended half-life B-cell depleting bispecific T-cell engager for development in autoimmune disease. Xencor plans to initiate a first-in-human study in the second half of 2025.



    • TL1A x IL23 Program: a bispecific antibody for dual targeting of important inflammatory pathways in autoimmune and inflammatory disease, while avoiding the complexities of dosing and formulary access for two separate TL1A and IL23 targeted drugs. Xencor anticipates selecting a lead candidate in 2025 and initiating first-in-human studies during 2026.

    Recent Partnership Developments

    • Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen is advancing for the treatment of patients with prostate cancer. In the fourth quarter of 2024, Amgen initiated a Phase 3 study of xaluritamig in patients with mCRPC who have previously been treated with taxane-based chemotherapy. We earned $30 million in milestone revenue, which we received in 2025. Multiple Phase 1 or Phase 1b studies evaluating xaluritamig as a monotherapy or in combination are enrolling patients with earlier prostate cancer.



    • Novartis: In the fourth quarter of 2024, Novartis initiated a Phase 2 study to evaluate an investigational antibody that incorporates an XmAb Fc domain, and Xencor earned $4 million in milestone revenue, which we received in 2025.

    Financial Guidance: Based on current operating plans, Xencor expects to end 2025 with between $535 million and $585 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.

    Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024

    Cash, cash equivalents, and marketable debt securities totaled $706.7 million as of December 31, 2024 compared to $697.0 million as of December 31, 2023.

    Total revenue for the fourth quarter ended December 31, 2024 was $52.8 million compared to $51.0 million for the same period in 2023. Revenue earned in the fourth quarter of 2024 was primarily the milestone revenue from Amgen and Novartis, as well as non-cash royalty revenue from Ultomiris and Monjuvi compared to the same period in 2023, which was primarily the research and milestone revenue from the two J&J collaboration agreements and non-cash royalty revenue from Ultomiris and Monjuvi. Revenue for the full year ended December 31, 2024 was $110.5 million compared to $174.6 million for the same period in 2023. Revenue in 2024 was primarily milestone revenue from Amgen and Novartis, licensing revenue, as well as non-cash royalty revenue from Ultomiris and Monjuvi compared to 2023, which was primarily milestone revenue from Alexion, Gilead, J&J, Omeros and Zenas and collaboration revenue from the second J&J collaboration.

    Research and development (R&D) expenses for the fourth quarter ended December 31, 2024 were $51.1 million compared to $63.0 million for the same period in 2023. R&D expenses for the full year ended December 31, 2024 were $227.7 million compared to $253.6 million for the same period in 2023. Lower R&D expenses reflect decreased spending on the wind down costs of terminated programs, partially offset by increased spending on programs such as XmAb819, XmAb657 and XmAb942.

    General and administrative (G&A) expenses for the fourth quarter ended December 31, 2024 were $14.9 million compared to $15.3 million for the same period in 2023. G&A expenses for the full year ended December 31, 2024 were $61.2 million compared to $53.4 million for the same period in 2023. Increased G&A spending reflects additional compensation costs on general and administrative staffing and spending on professional fees.

    Other expense, net for the fourth quarter ended December 31, 2024 was $31.4 million compared to other income, net of $14.7 million for the same period in 2023. Other expense, net for the full year ended December 31, 2024 was $56.5 million compared to other income, net of $12.7 million in the same period in 2023.

    Net loss attributable to Xencor for the fourth quarter ended December 31, 2024 was $45.6 million or $(0.62) on a fully diluted per share basis compared to net loss of $26.1 million or $(0.43) on a fully diluted per share basis, for the same period in 2023. For the full year ended December 31, 2024 net loss attributable to Xencor was $232.6 million or $(3.58) on a fully diluted per share basis compared to net loss of $133.1 million or $(2.20) on a fully diluted per share basis, for the same period in 2023.

    Upcoming Investor Conferences

    Company management will participate at multiple upcoming investor conferences:

    • TD Cowen 45th Annual Health Care Conference

      Date: Tuesday, March 4, 2025

      Presentation Time: 11:10 a.m. ET / 8:10 a.m. PT



    • Leerink Partners Global Healthcare Conference

      Date: Tuesday, March 11, 2025

      Presentation Time: 2:20 p.m. ET / 11:20 a.m. PT

    Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

    About Xencor

    Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

    Forward-Looking Statements

    Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," and similar terms, or by express or implied discussions relating to Xencor's business, including, but not limited to, statements regarding expectations and opportunities for clinical progress and success, expectations regarding advancement within Xencor's portfolio, expectations regarding clinical milestones, planned receipt and presentations of clinical data, including the expected timing thereof, XmAb candidates and programs, planned and ongoing clinical trials, including the expected timing thereof, projected financial resources and financial guidance, including estimated cash, cash equivalents and marketable debt securities at year end and cash runway for research and development programs and operations, the quotations from Xencor's chief executive officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2024 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    Xencor, Inc.
    Selected Consolidated Balance Sheet Data
    (in thousands)
     
    December 31, December 31,

     

    2024

     

    2023

     
    Cash, cash equivalents and marketable debt securities - current

    $

    449,846

    $

    551,515

    Other current assets

     

    127,755

     

    84,088

    Marketable debt securities - long term

     

    256,833

     

    145,512

    Other long-term assets

     

    117,511

     

    184,020

    Total assets

    $

    951,945

    $

    965,135

     
    Total current liabilities

    $

    87,432

    $

    73,915

    Debt - long term

     

    115,159

     

    161,772

    Other long term liabilities

     

    75,328

     

    67,361

    Total liabilities

     

    277,919

     

    303,048

    Total stockholders' equity

     

    674,026

     

    662,087

    Total liabilities and stockholders' equity

    $

    951,945

    $

    965,135

     
    Xencor, Inc.
    Consolidated Statements of Comprehensive Loss
    (in thousands, except share and per share data)
     
    Three Months Ended December 31, Year Ended December 31,

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

    (Unaudited)
    Revenue

    $

    52,794

     

    $

    50,966

     

    $

    110,493

     

    $

    174,615

     

     
    Operating expenses
    Research and development

     

    51,056

     

     

    63,046

     

     

    227,686

     

     

    253,598

     

    General and administrative

     

    14,916

     

     

    15,272

     

     

    61,215

     

     

    53,379

     

    Total operating expenses

     

    65,972

     

     

    78,318

     

     

    288,901

     

     

    306,977

     

    Loss from operations

     

    (13,178

    )

     

    (27,352

    )

     

    (178,408

    )

     

    (132,362

    )

     
    Other income (expense), net

     

    (31,404

    )

     

    14,705

     

     

    (56,515

    )

     

    12,728

     

    Loss before income tax

     

    (44,582

    )

     

    (12,647

    )

     

    (234,923

    )

     

    (119,634

    )

     
    Income tax expense

     

    1,617

     

     

    13,663

     

     

    1,617

     

     

    13,662

     

    Net loss

     

    (46,199

    )

     

    (26,310

    )

     

    (236,540

    )

     

    (133,296

    )

     
    Net loss attributable to non-controlling interest

     

    (647

    )

     

    (163

    )

     

    (3,922

    )

     

    (163

    )

    Net loss attributable to Xencor, Inc.

     

    (45,552

    )

     

    (26,147

    )

     

    (232,618

    )

     

    (133,133

    )

     
    Other comprehensive income (loss):
    Net unrealized (loss) gain on marketable debt securities available-for-sale

     

    (2,464

    )

     

    1,999

     

     

    (1,954

    )

     

    8,243

     

    Comprehensive loss attributable to Xencor, Inc.

    $

    (48,016

    )

    $

    (24,148

    )

    $

    (234,572

    )

    $

    (124,890

    )

     
    Net loss per common share attributable to Xencor, Inc.:
    Basic and Diluted

    $

    (0.62

    )

    $

    (0.43

    )

    $

    (3.58

    )

    $

    (2.20

    )

    Weighted average common shares used to compute net loss per share attributable to Xencor, Inc.
    Basic and Diluted

     

    73,175,549

     

     

    60,847,854

     

     

    65,041,265

     

     

    60,503,283

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250226858165/en/

    For Investors:

    Charles Liles

    [email protected]

    (626) 737-8118

    For Media:

    Cassidy McClain

    Inizio Evoke

    [email protected]

    (619) 694-6291

    Get the next $XNCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    2/28/2024$37.00 → $24.00Overweight → Neutral
    Piper Sandler
    5/19/2023$42.00Buy
    BofA Securities
    12/6/2022Outperform
    Cowen
    10/13/2022$58.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xencor Reports First Quarter 2025 Financial Results

      -- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Chief development officer and former independent director, Nancy Valente, M.D., to transition to senior advisory role -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. "Recently presented interim Phase 1 results suppo

      5/7/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Development Officer Valente Nancy sold $50,914 worth of shares (4,616 units at $11.03), decreasing direct ownership by 9% to 49,169 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      5/6/25 4:40:24 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VICE PRESIDENT & CFO Cornelissen Bart Jan sold $30,233 worth of shares (3,750 units at $8.06), decreasing direct ownership by 6% to 61,348 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      4/14/25 4:13:39 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Simpson Todd E

      4 - Xencor Inc (0001326732) (Issuer)

      3/13/25 7:03:03 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Financials

    Live finance-specific insights

    See more
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

      – Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 – – Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses – – Management hosting webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing

      9/9/24 7:31:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. The live webcast may be accessed through "E

      9/6/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Bart Cornelissen as Chief Financial Officer

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

      4/9/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of biopharmaceutical product development experience, and she most recently served as chief medical officer and chief development officer at Sierra Oncology through mid-2023. While at Sierra Oncology, she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of Ojjaara™ for myelofibrosis following the company's acquisition by GSK. "D

      9/19/23 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Xencor Inc.

      10-Q - Xencor Inc (0001326732) (Filer)

      5/7/25 4:09:38 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Xencor Inc (0001326732) (Filer)

      5/7/25 4:03:09 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xencor Inc.

      DEFA14A - Xencor Inc (0001326732) (Filer)

      4/23/25 4:06:50 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 6:16:13 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 1:22:36 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/12/24 4:01:23 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      2/15/24 4:02:46 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Xencor

      William Blair initiated coverage of Xencor with a rating of Outperform

      4/21/25 8:40:03 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Xencor with a new price target

      Wells Fargo initiated coverage of Xencor with a rating of Overweight and set a new price target of $37.00

      12/12/24 8:18:37 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Xencor from Neutral to Overweight and set a new price target of $30.00 from $20.00 previously

      12/2/24 10:12:11 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care